Mm Asct Eligibility

---
name: mm-asct-eligibility
description: Decide whether a newly-diagnosed multiple myeloma (NDMM) patient is eligible for high-dose melphalan + autologous stem cell transplantation (ASCT) as part of front-line therapy, using the EHA-ESMO 2021 criteria. Trigger when a clinician asks "is this myeloma patient fit for transplant", "ASCT eligibility for myeloma", "transplant-eligible NDMM", "should I refer for stem cell transplant", "high-dose melphalan candidate", or any decision about whether a newly-diagnosed myeloma patient should go to upfront ASCT.
---

# Multiple Myeloma — ASCT Eligibility (Front-Line)

Use this skill when a patient with **newly diagnosed multiple myeloma (NDMM)** has just been diagnosed, *before* selecting an induction regimen — because eligibility for ASCT changes the front-line plan.

---

## STEP 1 — Apply the primary eligibility filter

Eligible for HDT + ASCT if **ALL** of the following are true:

1. **Age <70 years** (chronological).
2. **No significant comorbidities** that would preclude high-dose melphalan or stem cell mobilisation.
3. **Adequate organ function** (cardiac, pulmonary, hepatic, renal — assess case-by-case).
4. **Performance status** consistent with tolerating intensive therapy.

If **all four** are met → **eligible for ASCT**. Go to Step 3.
If **any one** fails → likely ineligible. Go to Step 2.

---

## STEP 2 — Borderline cases (age 70–75 or single comorbidity)

The age cut-off is not absolute. A fit 72-year-old with no comorbidities may still benefit from ASCT, while a 65-year-old with severe COPD may not. Consider:

- **Biological vs. chronological age** — frailty score, IMWG frailty index, or geriatric assessment.
- **Renal impairment alone is NOT a contraindication** — ASCT is feasible in dialysis-dependent patients with melphalan dose reduction (140 mg/m²).
- **Cardiac comorbidity** (EF <40%, severe valvular disease) is a more rigid contraindication than renal disease.
- **Patient preference** matters — discuss the PFS benefit (~14-month gain in mPFS) vs. transplant-related morbidity.

If still unclear → refer for transplant assessment rather than rule out unilaterally.

---

## STEP 3 — Front-line plan for ASCT-ELIGIBLE patients

Recommended sequence:

1. **Induction** (4–6 cycles)
   - First option: **DaraVTD** [I, A] — new standard of care
   - Alternative: **VRd** [II, B] — best risk-benefit among triplets but not EMA-approved for this indication
   - If first option not available: **VTD** [I, A] or **VCD** [II, B]
2. **Stem cell mobilisation + harvest**
3. **Conditioning: HDM 200 mg/m²** [I, A] (reduce to 140 mg/m² for severe renal impairment)
4. **ASCT**
5. **Consolidation** (optional)
   - 2 cycles of VRd if VCD was used for induction [II, B]
   - **Tandem ASCT** for high-risk cytogenetics (del17p, t(4;14), t(14;16), 1q gain) or after VCD induction [II, B]
6. **Maintenance: lenalidomide until progression** [I, A]
   - Bortezomib may be considered for high-risk disease [II, B]

---

## STEP 4 — Front-line plan for ASCT-INELIGIBLE patients

If ineligible, switch to a transplant-ineligible regimen. Three new standards of care:
- **DaraRd** [I, A] — until progression
- **DaraVMP** [I, A] — 9 cycles VMP + Dara, then Dara until progression
- **VRd** [I, A] — preferred if Dara-based regimen not available

Less-preferred alternatives if none of the above are accessible:
- **VMP** [I, A]
- **Rd** [I, A]

For frail elderly patients (≥75y or frailty index intermediate/high), apply dose reductions per IMWG frailty consensus.

---

## CLINICAL GUARDRAILS

- **Don't rule out ASCT on age alone** if the patient is fit — transplant centres routinely accept patients up to 75. The "<70" cut-off is a guideline default, not a hard ceiling.
- **Renal failure / dialysis is NOT a contraindication** to ASCT — use HDM 140 mg/m².
- **Cardiac dysfunction (EF <40%) and severe pulmonary disease** are the most rigid hard stops.
- **Allo-SCT post-ASCT is NOT recommended** for high-risk disease — tandem ASCT gives equivalent or better OS with lower TRM (10-year data).
- **Decide on induction regimen knowing the ASCT plan** — DaraVTD, VTD, VCD, and VRd are designed to preserve stem cell yield. Avoid prolonged lenalidomide pre-harvest if ASCT is planned (>4 cycles can compromise mobilisation).
- **Don't delay the eligibility decision** — induction regimen choice depends on it. Make the call at the time of diagnosis, not after 3 cycles.

---

## SOURCE

Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 2021;32(3):309–322. DOI: 10.1016/j.annonc.2020.11.014

Adapted from the front-line therapy section and Figure 1.